ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

balstilimab

Also written as “Balstilimab”, “AGEN2034” and “Balstilimab + Zalifrelimab”.

Its studies are mostly in Uterine Cervical Neoplasms · Colorectal Neoplasms · Prostatic Neoplasms · Neoplasms · Hemangiosarcoma, led by 3 companies.

Drug pageBalstilimab: every studyAll 38 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 4, 202110 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agenusits history only81 open or runningphase 3since Jun 4, 2021Mar 27, 2017Sep 2027phase 2 · NCT05608044
ImmunoGenesis11 open or runningphase 2since Jan 9, 2025Jan 9, 2025Oct 2027phase 2 · NCT06782555
Rottapharm Biotechits history only11 open or runningphase 2since Jan 20, 2022Jan 20, 2022Dec 2026phase 2 · NCT05205330

Also a collaborator on its studies: Betta Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of ImmunoGenesis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2018Named balstilimabINNProposed as its International Nonproprietary Name in WHO's List 120 · before, AGEN2034
  2. Jan 9, 2025First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT06782555 · 71 enrolled · United States

Ahead

  1. Oct 2027Primary completion: phase 2 study in Prostatic NeoplasmsNCT06782555

TargetBeta

PDCD1 →read by rule
“A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1) protein, ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

The one study ImmunoGenesis leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06782555Prostatic Neoplasms · United States2Active, not recruitingOct 202771

How it is read

Names in the registry

  • “Balstilimab”, 4 entries
  • “AGEN2034”, 4 entries
  • “Balstilimab + Zalifrelimab”, 1 entry
  • “Balstilimab (BAL)”, 1 entry
  • “AGEN1223 and balstilimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.